Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-08-29, Stock:LLY, The news for the past five days is as follows:
2019-08-22: NEWS1: AstraZeneca's Kidney Drug Roxadustat Gets Second Nod in China.NEWS2: Health insurers will expand ACA coverage in 2020.
2019-08-23: NEWS1: Will Lawsuits Sink Johnson & Johnson Stock?.NEWS2: Will Lawsuits Sink Johnson & Johnson Stock?.NEWS3: Lilly Announces Top-Line Phase 3 Results for Oral JAK Inhibitor Baricitinib, in Combination with Topical Corticosteroids in Adult Patients with Moderate to Severe Atopic Dermatitis.NEWS4: Will Lawsuits Sink Johnson & Johnson Stock?.NEWS5: Arbitration panel rules in favor of Lilly in complaint filed by Adocia.NEWS6: AstraZeneca's Kidney Drug Roxadustat Gets Second Nod in China.NEWS7: AstraZeneca's Kidney Drug Roxadustat Gets Second Nod in China.
2019-08-26: NEWS1: Lilly's Olumiant Meets Primary Endpoint in 3rd Eczema Study.NEWS2: Lilly's Olumiant Meets Primary Endpoint in 3rd Eczema Study.NEWS3: Lilly's Olumiant Meets Primary Endpoint in 3rd Eczema Study.NEWS4: Lilly Receives U.S. FDA Approval for Taltz® (ixekizumab) for the Treatment of Active Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis).
2019-08-27: NEWS1: AstraZeneca's Farxiga Gets Fast Track Tag for Renal Outcome.NEWS2: AstraZeneca's Farxiga Gets Fast Track Tag for Renal Outcome.NEWS3: Lilly's (LLY) Taltz Gets FDA Nod for Ankylosing Spondylitis.NEWS4: Lilly's (LLY) Taltz Gets FDA Nod for Ankylosing Spondylitis.NEWS5: Lilly's (LLY) Taltz Gets FDA Nod for Ankylosing Spondylitis.NEWS6: AstraZeneca's Farxiga Gets Fast Track Tag for Renal Outcome.
2019-08-28: NEWS1: J&J (JNJ) Loses Landmark Opioid Case: What's Next for Pharmaceuticals?.NEWS2: J&J (JNJ) Loses Landmark Opioid Case: What's Next for Pharmaceuticals?.NEWS3: J&J (JNJ) Loses Landmark Opioid Case: What's Next for Pharmaceuticals?.

Answer: Rise